MCK logo

McKesson Corporation (MCK)

$1,079.79

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on MCK

Market cap

$124.67B

EPS

38.8

P/E ratio

25.1

Price to sales

0.27

Dividend yield

0.348%

Beta

0.274771

Price on MCK

Previous close

$1,082.59

Today's open

$1,075.23

Day's range

$1,067.38 - $1,081.47

52 week range

$723.68 - $1,121.50

Profile about MCK

CEO

Brian S. Tyler

Employees

43000

Headquarters

Irving, TX

Exchange

New York Stock Exchange

Shares outstanding

115456664

Issue type

Common Stock

MCK industries and sectors

Healthcare

Medical Distributors

News on MCK

Sales of Pharmaceuticals, GLP-1s Send McKesson Shares to New Highs

McKesson Corporation (MCK) shares up over 235% since May 2022 thanks to institutional support.

news source

FXEmpire • Nov 11, 2026

news preview

Here is What to Know Beyond Why McKesson Corporation (MCK) is a Trending Stock

Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.

news source

Zacks Investment Research • Nov 11, 2026

news preview

3 Reasons Why Growth Investors Shouldn't Overlook McKesson (MCK)

McKesson (MCK) could produce exceptional returns because of its solid growth attributes.

news source

Zacks Investment Research • Nov 10, 2026

news preview

McKesson Q2 Earnings Call Highlights

McKesson NYSE: MCK raised its fiscal 2027 adjusted earnings outlook after reporting higher second-quarter revenue and profit, supported by prescription volumes, specialty distribution and demand for medication access services.

news source

MarketBeat • Nov 7, 2026

news preview

McKesson Corporation (MCK) Hit a 52 Week High, Can the Run Continue?

McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

news source

Zacks Investment Research • Nov 6, 2026

news preview

McKesson (MCK) Upgraded to Buy: Here's What You Should Know

McKesson (MCK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

news source

Zacks Investment Research • Nov 6, 2026

news preview

MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised

McKesson's Q2 fiscal 2027 earnings beat estimates on specialty growth and higher prescription volumes, prompting raised guidance despite an after-hours stock dip.

news source

Zacks Investment Research • Nov 5, 2026

news preview

MCK Q2 Earnings Call Highlights Raised Outlook and Specialty Growth

McKesson raises its fiscal 2027 earnings outlook after strong Q2 results, fueled by specialty drug demand, operating gains and higher-margin healthcare expansion.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Bristol Gate U.S. Equity Q3 2026 Portfolio Review

Microsoft was the largest contributor, with its shares up 37.8% for the quarter. KLA and Applied Materials were the largest detractors, falling 35.3% and 29.2%. On a relative basis, three of the largest detractors were companies we did not own: NVIDIA, Apple, and Meta, which rose 14.3%, 15.2%, and 28.8%. We made one change to the portfolio during the quarter, purchasing Garmin and selling Verisk, and rebalanced outliers back to approximately equal weights during the same trade window.

news source

Seeking Alpha • Nov 5, 2026

news preview

The Biggest Drug Wholesaler Just Crushed Earnings Views — Here's What To Know

McKesson stock was flat late Wednesday, though the drug wholesaler topped fiscal second-quarter views and hiked its earnings guide.

news source

Investors Business Daily • Nov 4, 2026

news preview

¹ Disclosures

Get started with M1

Invest in McKesson Corporation

Open an M1 investment account to buy and sell McKesson Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in MCK on M1